KGI Increased the Value of Its Investment in Melinta Therapeutics shares about 200%

KGI significantly evaluated one of its current investments in the pharmaceutical industry. We took the opportunity and our expectations of an increase in portfolio investment in the US pharmaceutical company Melinta Therapeutics were confirmed. KGI obtained a return on the investment more than 200 %.

Melinta Therapeutics is a biotech company that specializes in the production and developement of new antibiotics. The American institution FDA (Food & Drug Administration) has recently confirmed that it will be testing further use of the existing medicine Baxdela which is currently used mainly for skin diseases. The market appreciated this fact by a significant increase of company value.

Pharmaceutical industry and health care is a sector, where KGI has an excellent know-how and evaluation of investment in the company Melinta Therapeutics confirms that we are able to find and exploit attractive opportunities offered by the market in this area.